Osteoporosis-related fractures could cost Medicaid more than $6 billion in hospital costs

Approximately 2.3 Million Fractures Suffered by 2 Million on Medicare; Proven Preventive Measures Go Largely Unused Source NOF A new report released today by the National Osteoporosis Foundation (NOF) finds that despite the existence of proven preventive measures, approximately 2 million Americans on Medicare suffered 2.3 million osteoporosis-related bone fractures in 2015. These totals mean osteoporotic

Read More


#Snack Tax may be more effective than a #Sugary Drink Tax To Tackle Obesity

Taxing sugary snacks like cookies and cakes may have a substantially larger impact in fighting obesity than levies on sweetened drinks, suggests a new study. Using economic modeling, UK researchers found that increasing sugary snack prices by 20% had an effect on annual calorie intake, body mass index (BMI), and obesity prevalence much greater than that of a

Read More


FDA approves first of its kind device to treat pediatric patients with progressive idiopathic scoliosis

The U.S. Food and Drug Administration today approved the first spinal tether device intended to be used in children and adolescents to correct the most common form of scoliosis, called idiopathic scoliosis, that has not responded to conservative treatment options, such as external bracing. The device, called The Tether – Vertebral Body Tethering System, is

Read More


Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans

Alternate-day fasting (ADF) had positive effects on body weight, cardiovascular measures, and molecular markers of aging when assessed in a randomized controlled trial among healthy adults without obesity or diabetes, researchers report in a study published online August 27 in Cell Metabolism. ADF is a different approach to control weight than the common caloric restriction (CR) or intermittent fasting (IF)

Read More


European Medicines Agency validates marketing application for Filgotinib for the treatment of rheumatoid arthritis

Gilead Sciences and Galapagos announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important

Read More